IOVA Iovance Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IOVA

Price (delayed)

$7.55

Market cap

$1.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$1.23B

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
The company's quick ratio rose by 39% QoQ and by 14% YoY
IOVA's equity is up by 33% since the previous quarter and by 21% year-on-year
The EPS has contracted by 4.8% YoY but it has grown by 3.6% from the previous quarter
Iovance Biotherapeutics's debt has increased by 4.2% YoY but it has decreased by 2.6% from the previous quarter
Iovance Biotherapeutics's net income has decreased by 15% YoY and by 4% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iovance.com
Peers: NRC NWBO

Key stats

What are the main financial stats of IOVA
Market
Shares outstanding
224.45M
Market cap
$1.69B
Enterprise value
$1.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$411.66M
EBITDA
-$389.8M
Free cash flow
-$333.42M
Per share
EPS
-$2.4
Free cash flow per share
-$1.56
Book value per share
$2.97
Revenue per share
$0
TBVPS
$3.86
Balance sheet
Total assets
$824.77M
Total liabilities
$157.89M
Debt
$83.23M
Equity
$666.88M
Working capital
$550.51M
Liquidity
Debt to equity
0.12
Current ratio
7.31
Quick ratio
7.25
Net debt/EBITDA
1.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.2%
Return on equity
-81%
Return on invested capital
-101.3%
Return on capital employed
-55.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
-1.82%
1 week
2.58%
1 month
38.03%
1 year
-50.07%
YTD
18.15%
QTD
23.57%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$418.02M
Net income
-$411.66M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 16% YoY and by 4.8% QoQ
Iovance Biotherapeutics's net income has decreased by 15% YoY and by 4% QoQ

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
2.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 4.8% YoY but it has grown by 3.6% from the previous quarter
IOVA's price to book (P/B) is 56% less than its 5-year quarterly average of 5.8 and 12% less than its last 4 quarters average of 2.9
IOVA's equity is up by 33% since the previous quarter and by 21% year-on-year

Efficiency

How efficient is Iovance Biotherapeutics business performance
Iovance Biotherapeutics's ROIC has plunged by 99% YoY and by 25% from the previous quarter
The ROE has declined by 48% year-on-year
The return on assets has declined by 37% year-on-year

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The current ratio has increased by 40% from the previous quarter and by 15% YoY
The company's quick ratio rose by 39% QoQ and by 14% YoY
Iovance Biotherapeutics's debt is 88% less than its equity
IOVA's equity is up by 33% since the previous quarter and by 21% year-on-year
IOVA's debt to equity is down by 29% from the previous quarter and by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.